Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline
Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
Global Cement Industry Reports 25% CO2 Intensity Reduction and Calls for Urgent Government Action to Accelerate Net Zero Mission
OpenAI and Capco Announce Services Partnership to Accelerate the Transformation of the Global Financial Services and Energy Sectors
Singapore International Foundation, SingHealth & Tamil Nadu DPHPM Strengthen Maternal & Child Health Through Decade-Long Collaboration